Valuation: Norda ASA

Market Cap 513M 55.23M 49.34M 45.32M 41.16M 77.3M 5.23B 79.24M 541M 218M 2.76B 207M 203M 8.75B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.45M 25.42M 23.35M 21.2M 39.82M 2.7B 40.82M 279M 112M 1.42B 107M 105M 4.51B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.06%
1 month+1.06%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 month 86
Extreme 86
86
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%-.--%+6.17%+109.76% 47.58M
-2.43%-4.38%+40.32%+55.64% 62.23B
+0.61%+1.10%+11.79%+70.22% 54.92B
+0.62%+2.74%+17.68%+103.81% 55.26B
+1.61%-3.30%+22.77%+33.16% 42.59B
-1.74%-3.02%+13.83%+93.17% 41.08B
+3.22%+4.30%+227.37%+776.49% 40.33B
+0.57%+25.47%+102.34%+88.40% 33.12B
-1.09%-0.05%+13.55%+45.35% 32.61B
-4.46%+9.98%-43.92%+320.28% 23.98B
Average -0.20%+3.17%+41.19%+169.63% 38.62B
Weighted average by Cap. -0.21%+2.12%+45.63%+159.79%

Financials

2023 2024
Net sales 86.92M 9.35M 8.36M 7.68M 6.97M 13.09M 886M 13.42M 91.64M 36.86M 468M 35.11M 34.36M 1.48B 372M 40.02M 35.75M 32.84M 29.83M 56.01M 3.79B 57.42M 392M 158M 2B 150M 147M 6.34B
Net income 31.17M 3.35M 3M 2.75M 2.5M 4.7M 318M 4.81M 32.86M 13.22M 168M 12.59M 12.32M 532M 126M 13.55M 12.11M 11.12M 10.1M 18.97M 1.28B 19.45M 133M 53.41M 678M 50.88M 49.79M 2.15B
Net Debt -311M -33.5M -29.93M -27.49M -24.97M -46.88M -3.17B -48.06M -328M -132M -1.67B -126M -123M -5.31B -249M -26.78M -23.92M -21.98M -19.96M -37.48M -2.54B -38.42M -262M -106M -1.34B -101M -98.37M -4.24B
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock